Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?

European Journal of Nuclear Medicine

Volumn 24, Issue 6, 1997, Pages 691-705

  Brock, C S ^a   Meikle, S R ^b   Price, R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

FDG; Oncology; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW;

DEOXYGLUCOSE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030877988     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050108     Document Type: Review

References (136)

1. Office of Population Censuses and Surveys. Cancer statistics registrations. Series MB1 no. 21, 1993.
2. de Silva R, Yamamoto Y, Rhodes CG, et al. Preoperative prediction of the outcome of coronary revascularization using positron emission tomography. Circulation 1992; 86: 1738-1742.
3. Ragosta M, Beller GA. The noninvasive assessment of myocardial viability. Clin Cardiol 1993; 16: 531-538.
4. Schelbert HR, Henze E, Phelps ME, Kuhl DE. Assessment of regional myocardial ischemia by positron-emission computed tomography. Am Heart J 1982; 103: 588-597.
5. Kushner M, Reivich M, Fieschi C, et al. Metabolic and clinical correlates of acute ischemic infarction. Neurology 1987; 37: 1103-1110.
6. Kushner M, Fieschi C, Alavi A, Silver F, Chawluk J, Reivich M. Local cerebral metabolic changes in acute ischemic strokes. Gerontology 1987; 33: 265-267.
7. Engel J Jr, Kuhl DE, Phelps ME, Crandall PH. Comparative localization of epileptic foci in partial epilepsy by PCT and EEG. Ann Neurol 1982; 12: 529-537.
8. Kumar A, Schapiro MB, Grady C, et al. High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology 1991; 4: 35-46.
9. Warburg O. The metabolism of tumors. New York: Richard Smith; 1931: 129-169.
10. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897-916.
11. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6: 371-388.
12. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670-675.
13. 18F]-2- fluoro-2-deoxy-D-mannose: a new tracer for cancer detection. Eur J Nucl Med 1982; 7: 294-297.
14. 18F-2-fluoro-2-deoxy-D-glucose. Eur J Nucl Med 1986; 12: 325-328.
15. 14C]-glucose during chemotherapy in murine Lewis lung tumor. Int J Rad Appl Instrum [B] 1992; 19: 55-63.
16. 18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-1329.
17. Patronas NJ, Brooks RA, DeLaPaz RL, Smith BH, Kornblith PL, Di Chiro G. Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. AJNR Am J Neuroradiol 1983; 4: 533-535.
18. Rhodes CG, Wise RJ, Gibbs JM, et al. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 1983; 14: 614-626.
19. 18F]fluoro-2-deoxyglucose in tumorbearing rats: chromatographic and enzymatic studies. Int J Rad Appl Instrum [B] 1986; 13: 577-581.
20. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235: 1492-1495.
21. Farina FA, Adelman RC, Lo CH, Morris HP, Weinhouse S. Metabolic regulation and enzyme alterations in the Morris hepatomas. Cancer Res 1968; 28: 1897-1900.
22. Shatton JB, Morris HP, Weinhouse S, Kinetic, electrophoretic, and chromatographic studies on glucose-ATP phosphotransferases in rat hepatomas. Cancer Res 1969; 29: 1161-1172.
23. Kikuchi Y, Sato S, Sugimura T. Hexokinase isozyme patterns of human uterine tumors. Cancer 1972; 30: 444-447.
24. Bennett MJ, Timperley WR, Taylor CB, Hill AS. Isoenzymes of hexokinase in the developing, normal and neoplastic human brain. Eur J Cancer 1978; 14: 189-193.
25. Weber G. Enzymology of cancer cells (second of two parts). N Engl J Med 1977; 296: 541-551.
26. Weber G. Enzymology of cancer cells (first of two parts). N Engl J Med 1977; 296: 486-492.
27. 19F NMR rotating frame zeugmatography: one dimensional chemical shift imaging of normal and gliosarcoma implanted brain. Magn Reson Imaging 1987; 5: 259-266.
28. Coleman MT, Allen N. The hexose monophosphate pathway in ethylnitrosourea induced tumors of the nervous system. J Neurochem 1978; 30: 83-90.
29. Haberkorn U, Strauss LG, Reisser C, et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry [see comments]. J Nucl Med 1991; 32: 1548-1555.
30. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33: 325-329.
31. Reisser C, Haberkorn U, Strauss LG. The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors. J Otolaryngol 1993; 22: 231-238.
32. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32: 1508-1512.
33. Francavilla TL, Miletich RS, Di Chiro G, Patronas NJ, Rizzoli HV, Wright DC. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 1989; 24: 1-5.
34. Tyler JL, Diksic M, Villemure JG, et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987; 28: 1123-1133.
35. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61: 1776-1781.
36. Slosman DO, Spiliopoulos A, Couson F, et al. Satellite PET and lung cancer: a prospective study in surgical patients. Nucl Med Commun 1993; 14: 955-961.
37. Adler LP, Crowe JP, Al Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-750.
38. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D- glucose. Radiology 1991; 179: 765-770.
39. Hanson MW, Glantz MJ, Hoffman JM, et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 1991; 15: 796-801.
40. Wahl RL, Helvie MA, Chang AE, Andersson I. Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. J Nucl Med 1994; 35: 872-875.
41. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216: 27-34.
42. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371-377.
43. Knopp MV, Strauss LG, Haberkorn U, et al. PET of the thorax: assessment of its clinical application in tumor staging [abstract]. Radiology 1990; 174.
44. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994; 81: 1666-1670.
45. 18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582-589.
46. 18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993; 51: 175-181.
47. Yoshikawi K, Okada J, Uno K, et al. Evaluation of therapeutic effect on the malignant lymphoma by dynamic positron emission tomography technique using fluorine-18-2-deoxy-2-fluoro-D-glucose [abstract]. J Nucl Med 1989; 30: 910.
48. Strauss LG, Tilgen W, Dimatrakopoulou A, Haberkorn U, Knopp M, Helius F. PET studies with F-18-deoxyglucose (FDG) in patients with metastatic melanoma prior to and after therapy [abstract]. J Nucl Med 1990; 31: 804.
49. Kubota K, Yamada S, Ishiwata K, Ito M, Ido T. Positron emission tomography for treatment evaluation and recurrence detection compared with CT in long-term follow-up cases of lung cancer. Clin Nucl Med 1992; 17: 877-881.
50. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment [see comments]. J Nucl Med 1992; 33: 333-339.
51. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101-2111.
52. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995; 13: 1470-1477.
53. Fukuda H, Matsuzawa T, Ito M, Abe Y, Yoshioka S, Yamada K. Experimental and clinical study of cancer diagnosis with (F-18) FDG using positron emission tomography. J Nucl Med 1984; 25: 50.
54. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32: 1485-1490.
55. Ito K, Kato T, Tadokoro M, et al. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992; 182: 549-552.
56. Greven KM, Williams Dr, Keyes JJ, et al. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. Int J Radiat Oncol Biol Phys 1994; 29: 841-845.
57. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 1988; 150: 189-197.
58. 18F]fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982; 144: 885-889.
59. Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH, Doyle WK. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 1988; 69: 830-838.
60. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989: 170: 329-332.
61. 18F]fluorodeoxyglucose positron emission tomography [see comments]. Ann Neurol 1991; 29: 347-355.
62. 11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991; 32: 197-202.
63. Lapela M, Grenman R, Kurki T, et al. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology 1995; 197: 205-211.
64. 18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993; 33: 540-548.
65. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985; 62: 816-822.
66. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988; 62: 1074-1078.
67. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991 ; 32: 686-691.
68. Mineura K, Sasajima T, Kowada M, et al. Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 1994; 73: 2386-2394.
69. Okada J, Oonishi H, Yoshikawa K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994; 8: 187-191.
70. Kennedy C, Sakurada O, Shinohara M, Jehle J, Sokoloff L. Local cerebral glucose utilization in the normal conscious macaque monkey. Ann Neurol 1978; 4: 293-301.
71. 11C]deoxyglucose. J Cereb Blood Flow Metab 1985; 5: 179-192.
72. Kumar A, Braun A, Schapiro M, Grady C, Carson R, Herscovitch P. Cerebral glucose metabolic rates after 30 and 45 minute acquisitions: a comparative study. J Nucl Med 1992; 33: 2103-2105.
73. Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986; 36: 879-887.
74. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35: 1308-1312.
75. Weinberg IN, Huang SC, Hoffman EJ, et al. Validation of PET-acquired input functions for cardiac studies [published erratum appears in J Nucl Med 1988; 29: 1304]. J Nucl Med 1988; 29: 241-247.
76. 18F]fluoro-2-deoxy-D-glucose studies. J Nucl Med 1991; 32: 733-738.
77. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med 1991; 32: 1432-1438.
78. Germano G, Chen BC, Huang SC, Gambhir SS, Hoffman FJ, Phelps ME. Use of the abdominal aorta for arterial input function determination in hepatic and renal PET studies [see comments]. J Nucl Med 1992; 33: 613-620.
79. Takikawa S, Dhawan V, Spetsieris P, et al. Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve. Radiology 1993; 188: 131-136.
80. Kessler RM, Ellis JR Jr, Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr 1984; 8: 514-522.
81. Kuwert T, Ganslandt T, Jansen P, et al. Influence of size of regions of interest on PET evaluation of caudate glucose consumption. J Comput Assist Tomogr 1992; 16: 789-794.
82. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography. 1. Effect of object size. J Comput Assist Tomogr 1979; 3: 299-308.
83. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36: 1836-1839.
84. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189: 847-850.
85. Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction [see comments]. J Nucl Med 1994; 35: 164-167.
86. Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993; 34: 355-359.
87. Lindholm P, Minn H, Leskinen KS, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study [see comments]. J Nucl Med 1993; 34: 1-6.
88. Nelson T, Lucignani G, Atlas S, Crane AM, Dienel GA, Sokoloff L. Reexamination of glucose-6-phosphatase activity in the brain in vivo: no evidence for a futile cycle. Science 1985; 229: 60-62.
89. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physol 1980; 238: E69-E82.
90. Hawkins RA, Phelps ME, Huang SC, Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET. J Cereb Blood Flow Metab 1986; 6: 170-183.
91. Kato A, Diksic M, Yamamoto YL, Feindel W, Quantification of glucose utilization in an experimental brain tumor model by the deoxyglucose method. J Cereb Blood Flow Metab 1985; 5: 108-114.
92. Kapoor R, Spence AM, Muzi M, Graham MM, Abbott GL, Krohn KA. Determination of the deoxyglucose and glucose phosphorylation ratio and the lumped constant in rat brain and a transplantable rat glioma. J Neurochem 1989; 53: 37-44.
93. Schuier F, Orzi F, Suda S, Lucignani G, Kennedy C, Sokoloff L. Influence of plasma glucose concentration on lumped constant of the deoxyglucose method: effects of hyperglycemia in the rat. J Cereb Blood Flow Metab 1990; 10: 765-773.
94. Fischman AJ, Alpert NM. FDG-PET in oncology: there's more to it than looking at pictures. J Nucl Med 1993; 34: 6-11.
95. Herholz K, Wienhard K, Heiss WD. Validity of PET studies in brain tumors. Cerebrovasc Brain Metab Rev 1990; 2: 240-265.
96. 18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab 1992; 12: 823-834.
97. Schmidt KC, Lucignani G, Sokoloff L. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilisation: a re-examination. J Nucl Med 1996; 37: 394-399.
98. Wu HM, Huang SC, Choi Y, Hoh CK, Hawkins RA. A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue. J Nucl Med 1995; 36: 297-306.
99. vom Dahl J, Herman WH, Hicks RJ, et al. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed quantitatively by dynamic positron emission tomography. Circulation 1993; 88: 395-404.
100. Bradbury MW, Kleeman CR. Stability of the potassium content of cerebrospinal fluid and brain. Am J Physiol 1967; 213: 519-528.
101. Gjedde A. High- and low-affinity transport of D-glucose from blood to brain. J Neurochem 1981; 36: 1463-1471.
102. Patlak CS, Blasberg RG, Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584-590.
103. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
104. 18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 1990; 31: 1831-1835.
105. 18F]fluorodeoxyglucose PET with glucose loading. J Comput Assist Tomogr 1994; 18: 12-15.
106. Horner HC, Packan DR, Sapolsky RM. Glucocorticoids inhibit glucose transport in cultured hippocampal neurons and glia. Neuroendocrinology 1990; 52: 57-64.
107. 82Rb: the effect of dexamethasone and whole-brain radiation therapy. Ann Neurol 1985; 18: 636-646.
108. Leenders KL, Beaney RP, Brooks DJ, Lammertsma AA, Heather JD, McKenzie CG. Dexamethasone treatment of brain tumor patients: effects on regional cerebral blood flow, blood volume, and oxygen utilization. Neurology 1985; 35: 1610-1616.
109. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 1995; 83: 657-664.
110. Theodore WH, Bairamian D, Newmark ME, et al. Effect of phenytoin on human cerebral glucose metabolism. J Cereb Blood Flow Metab 1986; 6: 315-320.
111. Theodore WH, DiChiro G, Margolin R, Fishbein D, Porter RJ, Brooks RA. Barbiturates reduce human cerebral glucose metabolism. Neurology 1986; 36: 60-64.
112. Theodore WH. Antiepileptic drugs and cerebral glucose metabolism. Epilepsia 1988; 29 Suppl 2: S48-S55.
113. Theodore WH, Bromfield E, Onorati L. The effect of carbamazepine on cerebral glucose metabolism. Ann Neurol 1989; 25: 516-520.
114. Leiderman DB, Balish M, Bromfield EB, Theodore WH. Effect of valproate on human cerebral glucose metabolism. Epilepsia 1991; 32: 417-422.
115. Baron JC, Frackowiak RS, Herholz K, et al. Use of PET methods for measurement of cerebral energy metabolism and hemodynamics in cerebrovascular disease. J Cereb Blood Flow Metab 1989; 9: 723-742.
116. Herholz K, Patlak CS. The influence of tissue heterogeneity on results of fitting nonlinear model equations to regional tracer uptake curves: with an application to compartmental models used in positron emission tomography. J Cereb Blood Flow Metab 1987; 7: 214-229.
117. Schmidt K, Mies G, Sokoloff L. Model of kinetic behavior of deoxyglucose in heterogeneous tissues in brain: a reinterpretation of the significance of parameters fitted to homogeneous tissue models. J Cereb Blood Flow Metab 1991; 11: 10-24.
118. Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 1995; 31a: 1924-1927.
119. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60: 2682-2689.
120. 18F]FDG. J Comput Assist Tomogr 1990; 14: 960-962.
121. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31: 1927-1932.
122. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992; 182: 185-194.
123. Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid 1993; 3: 195-200.
124. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993; 114: 728-734.
125. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34: 1420-1427.
126. Rege SD, Hoh CK, Glaspy JA, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72: 82-90.
127. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-3925.
128. Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994; 73: 3047-3058.
129. Holthoff VA, Herholz K, Berthold F, et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 1993; 72: 1394-1403.
130. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993; 34: 12-17.
131. Greven KM, Williams Dr, Keyes JJ, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation [see comments]. Cancer 1994; 74: 1355-1359.
132. Kubota K, Yamada K, Yoshioka S, Yamada S, Ito M, Ido T. Differential diagnosis of idiopathic fibrosis from malignant lymphadenopathy with PET and F-18 fluorodeoxyglucose. Clin Nucl Med 1992; 17: 361-363.
133. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995; 36: 788-793.
134. 18F]fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987; 22: 360-371.
135. Holzer T, Herholz K, Jeske J, Heiss WD. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 1993; 17: 681-687.
136. Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-3527.